SubHero Banner

Entacapone-Containing Products – Safety update

August 13, 2019 - The FDA announced that there is no increased risk of prostate cancer with the use of entacapone [ie, Comtan® (entacapone) and Stalevo® (carbidopa/levodopa/entacapone)] to treat Parkinson’s disease (PD) and the recommendations for using these medicines will remain the same as labeled in the prescribing information.

Download PDF